Effects of combined diuretic therapy on exercise capacity, alveolar-capillary diffusion and maintenance of euvolemia in chronic congestive heart failure, diuretic therapy compared with loop diuretics and potassium-sparing diuretics
Key facts
- Where
- Milan, OlaszországSee the site
- Phase
- 3. fázis
Where in Olaszország
- Centro Cardiologico Monzino S.p.A.Milan, OlaszországTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Centro Cardiologico Monzino S.p.A.
- Trial code
- EU 2024-519565-21-01
- Record updated
- 2025. december 18.
- Original description
To compare two different treatment strategies (control arm treated with loop diuretic and potassium sparing and experimental arm that will combine such therapy with acetazolamide and free-dose metolazone) in patients with chronic heart failure.Read full original descriptionShow less
To compare two different treatment strategies (control arm treated with loop diuretic and potassium sparing and experimental arm that will combine such therapy with acetazolamide and free-dose metolazone) in patients with chronic heart failure.
Inclusion: written informed consent signed; Age: 18-80; Patients with chronic heart failure (at reduced or preserved ejection fraction); Patients discharged after hospitalization for acute heart failure (at least second episode of decompensation in the past 12 months); Patients being treated with loop diuretics at the same or higher dosage of furosemide 40 mg (or equivalent) at the time of admission.
Exclusion: Medical therapy for heart failure optimized during hospitalization; patients with severe renal failure (eGFR<20 ml/min/1.73m2 according to CockroftGault); age <18 years or >85 years; patients with severe aortic stenosis; patients with severe hyponatremia; Documented current pregnancy and lactating status in women of childbearing potential.